| Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma E Saâda-Bouzid, C Defaucheux, A Karabajakian, VP Coloma, V Servois, ... Annals of Oncology 28 (7), 1605-1611, 2017 | 599 | 2017 |
| Induction chemotherapy in head and neck cancers: Results and controversies M Gau, A Karabajakian, T Reverdy, EM Neidhardt, J Fayette Oral Oncology 95, 164-169, 2019 | 81 | 2019 |
| Precision medicine approaches to overcome resistance to therapy in head and neck cancers S Ortiz-Cuaran, J Bouaoud, A Karabajakian, J Fayette, P Saintigny Frontiers in Oncology 11, 614332, 2021 | 42 | 2021 |
| Induction chemotherapy in head and neck squamous cell carcinoma: a question of belief A Karabajakian, M Gau, T Reverdy, EM Neidhardt, J Fayette Cancers 11 (1), 15, 2018 | 30 | 2018 |
| MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer M Prasad, J Zorea, S Jagadeeshan, AB Shnerb, S Mathukkada, ... Journal for ImmunoTherapy of Cancer 10 (3), 2022 | 25 | 2022 |
| Chemotherapy for recurrent/metastatic head and neck cancers A Karabajakian, P Toussaint, EM Neidhardt, V Paulus, P Saintigny, ... Anti-Cancer Drugs 28 (4), 357-361, 2017 | 21 | 2017 |
| Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma A Karabajakian, T Garrivier, C Crozes, N Gadot, JY Blay, F Bérard, ... Oncotarget 11 (18), 1618, 2020 | 19 | 2020 |
| Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule A Pêtre, C Dalban, A Karabajakian, EM Neidhardt, PE Roux, M Poupart, ... Oncotarget 9 (31), 22038, 2018 | 17 | 2018 |
| Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity A Karabajakian, J Bouaoud, L Michon, M Kamal, C Crozes, P Zrounba, ... Oral Oncology 119, 105368, 2021 | 16 | 2021 |
| Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients JP Foy, A Karabajakian, S Ortiz-Cuaran, M Boussageon, L Michon, ... European Journal of Cancer 174, 287-298, 2022 | 15 | 2022 |
| Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 … E Saada-Bouzid, C Defaucheux, A Karabajakian, V Palomar Coloma, ... Journal of Clinical Oncology 34 (15_suppl), 6072-6072, 2016 | 15 | 2016 |
| Molecular mechanisms of Kaposi sarcoma development A Karabajakian, I Ray-Coquard, JY Blay Cancers 14 (8), 1869, 2022 | 14 | 2022 |
| Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors JP Foy, A Karabajakian, S Ortiz-Cuaran, M Boussageon, L Michon, ... Data in Brief 44, 108556, 2022 | 8 | 2022 |
| Nivolumab in recurrent/metastatic head and neck cancers A Karabajakian, T Reverdy, M Gau, J Fayette Future Oncology 14 (7), 603-609, 2017 | 8 | 2017 |
| Head and neck cancer and immunotherapy: current knowledge and perspective T Gauduchon, T Reverdy, M Gau, A Karabajakian, L Collet, EM Neidhardt, ... J Cancer Metastasis Treat 5, 72, 2019 | 6 | 2019 |
| Chemotherapy for localized head and neck squamous cell cancers A Karabajakian, P Toussaint, EM Neidhardt, V Paulus, P Saintigny, ... Anti-Cancer Drugs 28 (4), 362-368, 2017 | 6 | 2017 |
| Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma A Karabajakian, T Garrivier, C Crozes, N Gadot, JY Blay, F Bérard, ... Oncotarget 13, 1305, 2022 | 2 | 2022 |
| Artificial intelligence–based biomarkers of response to immunotherapy in patients with non–small-cell lung cancer considering previous lines of treatment. P Iriso, J Boulahfa, M Afshar, V Attignon, J Bouaoud, M Boussageon, ... Journal of Clinical Oncology 41 (16_suppl), e14652-e14652, 2023 | 1 | 2023 |
| Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group A Karabajakian, C Genestie, P Meeus, F Guyon, S Croce, S Taieb, ... Bulletin du Cancer, S0007-4551 (23) 00212, 2023 | 1 | 2023 |
| Retrospective study of BRAF-mutant metastatic colorectal cancer patients and influence of the mismatch repair efficiency. L Mais, M Sarrabi, F Desseigne, P Guibert, C Castillo, M Foulfoin, ... Journal of Clinical Oncology 33 (15_suppl), e14677-e14677, 2015 | 1 | 2015 |
